The appointment is a standard organizational change and does not alter Eikon's pipeline or financial trajectory. Monitor for upcoming clinical data readouts or financing events for trading catalysts.
Price Chart
Executive Summary
Eikon Therapeutics appointed Dr. Ching-Pin Chang as EVP and Chief Scientific Officer. Dr. Chang joins from Bristol Myers Squibb and brings over two decades of cardiovascular and drug discovery experience. This is a routine leadership hire that does not change the company's near-term financial outlook or pipeline trajectory.
Key Facts
- Dr. Ching-Pin Chang appointed EVP and Chief Scientific Officer, effective immediately.
- Dr. Chang previously served as VP, Head of Cardiovascular Discovery Biology at Bristol Myers Squibb.
- He also held leadership roles at Gilead Sciences and MyoKardia, where he contributed to the characterization of mavacamten.
- Eikon is a late-stage clinical biopharmaceutical company focused on oncology.
Financial Impact
No financial terms disclosed; routine executive hire with no material financial impact.
Risk Factors
- No change to pipeline risk or financial outlook.
- Leadership additions alone rarely move stock prices.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3355784 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 23, 2026 3d ago | 8-K | $8.01 | awaiting T+20 | — | $6.68 (−16.57%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $6.68 (−11.37%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $6.68 (−8.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $6.68 (−25.58%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $6.68 (−37.72%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $6.68 (−39.03%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $6.68 (−39.52%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $6.68 (−30.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers